Etoxidol solution 50mg/ml 2ml ampoules, 10pcs

Composition

>

1 ml of solution for intravenous and intramuscular use contains:

Active ingredient:

ethylmethylhydroxypyridine malate (etoxidol) 50 mg

. excipients:

N-acetyl-L-glutamic acid 34 mg,

deanol (2-(dimethylamino)ethanol) 16 mg,

glycine 0.1 mg,

disodium edetate (disodium salt of ethylenediamine-N, N, N’, N’-tetraacetic acid 2-water [trilon B]) 0.5 mg,

water for injection up to 1.0 ml

Pharmacological action

It is an inhibitor of free radical processes, has a membrane-protective, antihypoxic, nootropic, anticonvulsant, anxiolytic effect, increases the body’s resistance to stress. It has anti-ischemic properties, improves blood flow in the ischemic zone, limits the area of ischemic damage, detects hypolipidemic action, reduces the content of total cholesterol and low-density lipoproteins. Increases the body’s resistance to various damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, alcohol intoxication and antipsychotic drugs (neuroleptics)).

Efficacy in encephalopathies is due to the penetration of ethoxidol through the blood-brain barrier. Improves brain metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Inhibits lipid peroxidation, increases the activity of superoxide dismutase, reduces the content of total organic peroxides, increases the lipid-protein ratio, reduces the viscosity of the membrane, increases its fluidity. Blocks the oxidation of low-density lipoproteins.

Modulates the activity of membrane-bound enzymes (calcium phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which helps preserve the structural and functional organization of biomembranes, transport neurotransmitters, and improves synaptic transmission.

When administered intravenously, it is determined in the blood plasma for 4 hours after use. TSmax – 0.25 h. T1/2 – 1,15-1,75 h. It is excreted by the kidneys, mainly in glucuronoconjugated form and in small amounts in unchanged form.

Indications

acute cerebral circulatory disorders,

dyscirculatory encephalopathy,

vegetative dystonia syndrome,

mild cognitive disorders of atherosclerotic origin,

anxiety disorders in neurotic and neurosis-like conditions,

relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders,

acute intoxication with antipsychotic drugs.

Use during pregnancy and lactation

Ethoxidol is contraindicated during pregnancy and lactation, as strictly controlled clinical studies of the safety of the drug during pregnancy and lactation have not been conducted.

Contraindications

Hypersensitivity, acute hepatic and / or renal failure, pregnancy, lactation, age up to 18 years.

With caution: Allergic diseases and reactions in the anamnesis.

Side effects

Dry, metallic taste in the mouth, the feeling of “heat spreading” throughout the body, sore throat and discomfort in the chest, feeling of shortage of air (usually associated with high rate of use and are short-term), long-term use, nausea, flatulence, and sleep disorder (sleepiness or poor sleep).

Interaction

Increases the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian agents (levodopa).

Reduces the toxic effects of ethyl alcohol.

How to take, course of use and dosage

Assign intramuscularly (iv) and intravenously (iv) (jet or drip). When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution. Doses are selected individually. Start with-50-100 mg 1-3 times / day, gradually increasing until a therapeutic effect is obtained. Jet slowly for 5-7 minutes, drip at a speed of 40-60 drops per minute. The maximum dose is 800 mg / day.

In acute disorders of cerebral circulation: in complex therapy in the first 2-4 days IV (drip) – 200-300 mg, then in / m, – 100 mg 3 times a day,10-14 days.

For dyscirculatory encephalopathy in the decompensation phase and vegetative dystonia syndrome: intravenous jet or drip – 100 mg 2-3 times a day,14 days. Then in / m, – 100 mg 2 times / day,14 days.

For the course prevention of dyscirculatory encephalopathy: in / m, – 100 mg 2 times / day,10-14 days.

For mild cognitive disorders of atherosclerotic origin and for anxiety disorders in neurotic and neurosis-like conditions: i / m, – 100-300 mg / day,14-30 days.

When stopping the withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders: in / m, – 100-200 mg 2-3 times/day or in / in drip-1-2 times/day,5-7 days.

In case of acute intoxication with antipsychotic drugs: iv, – 50-300 mg / day,7-14 days.

Overdose

Due to the low toxicity of the drug, overdose is unlikely. In case of accidental overdose, symptoms of sleep disorders may occur – drowsiness, insomnia.

Treatment is symptomatic.

Special instructions

During the treatment period, care should be taken when driving vehicles and engaging in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Form of production

Solution for intravenous and intramuscular use

Storage conditions

In a dark place at a temperature not exceeding 25°C. Keep out of reach of children.

Shelf life

3 years

Active ingredient

Ethylmethylhydroxypyridine malate

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection and infusion

Description

For adults as directed by your doctor

Indications

Exposure to adverse factors, Prevention of heart attacks and strokes, Stress, Atherosclerosis, Consequences of stroke